An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Catalent Appoints Ricardo Zayas as North American Biologics Operations Leader
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
management
Rhea-AI Summary
Catalent, Inc. (NYSE: CTLT) has appointed Ricardo Zayas as Senior Vice President of Operations for Biologics North America. Zayas will oversee North American biologics operations, including fill/finish services in Bloomington, Indiana and gene therapy manufacturing in Harmans, Maryland. Reporting to CEO Alessandro Maselli, Zayas brings over 30 years of experience in pharmaceutical manufacturing, having previously served as COO at Ocyonbio and holding leadership roles at Romark Pharmaceuticals and Bristol-Myers Squibb. This strategic appointment aims to enhance Catalent's operational excellence and support growth in innovative treatments.
Positive
Appointment of Ricardo Zayas expected to strengthen leadership and operational capabilities.
Zayas brings over 30 years of experience enhancing strategic growth in biologics.
Negative
Potential concerns about continuity given management changes in the leadership team.
SOMERSET, N.J.--(BUSINESS WIRE)--
Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced the appointment of Ricardo Zayas as Senior Vice President, Operations, Biologics North America. Mr. Zayas will be responsible for all of the company’s North American biologics operations, including its centers of excellence for drug product fill/finish in Bloomington, Indiana, and gene therapy manufacturing in Harmans, Maryland. He will serve on the Executive Leadership Team, reporting directly to Catalent’s President & Chief Executive Officer, Alessandro Maselli.
Ricardo Zayas, who joins Catalent as Senior Vice President, Operations, Biologics North America. (Photo: Business Wire)
Welcoming Mr. Zayas to Catalent, Alessandro Maselli commented, “Ricardo brings vast senior management experience to Catalent’s leadership team, which he will draw upon as we execute the next stage of our strategic growth plans in biologics that we have been implementing over the past few years. We have made significant investment in facilities, assets and new technologies across North America, and Ricardo will be working closely with the team we have in place to meet the demands of our customers’ therapies and medicines, enhancing operational excellence, and bringing a growing pipeline of innovative treatments to patients.”
Mr. Zayas’ experience includes more than 30 years working in pharmaceutical manufacturing and operations leadership. He joins Catalent from Ocyonbio, a biosimilars, cell and gene, and viral vector development and manufacturing company, where he was Chief Operating Officer. Prior to that, as Executive Vice President and Head of Operations for Romark Pharmaceuticals, he led the development and buildout of Romark’s new manufacturing facility in Puerto Rico. His career also includes seven years at Bristol-Myers Squibb, where he held the position of Senior Vice President, Global Pharmaceutical Manufacturing, Supply Chain, and Product Strategy, and led global pharmaceutical and API manufacturing, overseeing more than 8,000 employees worldwide. He has also held pharmaceutical manufacturing leadership roles at Sterling Drug, Warner-Lambert, Pfizer, Schering Plough, AMAG Pharmaceuticals, and Avon Products. He holds a bachelor’s degree in industrial engineering from Kansas State University, Manhattan, Kansas.
Notes for Editors
About Catalent
Catalent, Inc. (NYSE: CTLT), an S&P 500® company, is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs.
Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply around 80 billion doses of nearly 8,000 products annually. Catalent’s expert workforce of approximately 18,000 includes more than 3,000 scientists and technicians.
Headquartered in Somerset, New Jersey, the company generated nearly $5 billion in revenue in its 2022 fiscal year. For more information, visit www.catalent.com.
More products. Better treatments. Reliably supplied.™
